The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Prostate cancer: OR 1.04 (95% CI 0.98 to 1.09), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Type 2 diabetes: OR 0.63 (95% CI 0.56 to 0.69), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Sporadic colorectal adenoma recurrence: OR 0.87 (95% CI 0.57 to 1.33), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Ischaemic heart disease: HR 0.72 (95% CI 0.65 to 0.81), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Breast cancer (Premenopausal): RR 1.01 (95% CI 0.97 to 1.06), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality, Patients with chronic kidney disease: RR 0.86 (95% CI 0.81 to 0.92), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Metabolic syndrome (prevalent): OR 0.49 (95% CI 0.38 to 0.64), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Cognition: OR 0.42 (95% CI 0.34 to 0.53), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Pancreatic cancer: OR 2.13 (95% CI 1.02 to 4.47), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Hip fracture (Population-based controls): log ratio of geometric mean -0.51 (95% CI -0.64 to -0.38), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Non-Hodgkin's lymphoma (Females): OR 0.81 (95% CI 0.39 to 1.70), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Hypertension: RR 0.70 (95% CI 0.58 to 0.86), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.